Our Pricing

UK Weight Loss Jabs - All Doses In Stock Today

Published on: June 03, 2026

Searching for weight loss jabs UK all doses in stock? Cured Pharmacy maintains full availability across Mounjaro, Wegovy, and Saxenda — from starter doses through to maintenance pens. Our UK-registered clinical team provides free online consultations in under three minutes, with transparent upfront pricing and discreet next-day delivery across the United Kingdom.

How GLP-1 Weight Loss Jabs Work

Weight loss injections like Mounjaro, Wegovy, and Saxenda belong to a class of medications called GLP-1 receptor agonists, licensed by the MHRA for chronic weight management in adults with a BMI of 30 or above, or 27 with weight-related conditions [1]. These medications mimic the action of glucagon-like peptide-1, a natural hormone that regulates appetite, slows gastric emptying, and improves insulin sensitivity.

Mounjaro (tirzepatide) represents the latest advancement, working as a dual GIP/GLP-1 receptor agonist. In the SURPASS-2 trial, participants achieved an average body weight reduction of 22.5% over 72 weeks on the 15mg maintenance dose — the highest efficacy observed in any obesity medication trial to date [1]. Wegovy (semaglutide) demonstrated average weight loss of 14.9% in the STEP-1 trial, whilst Saxenda (liraglutide) showed 8% average reduction in the SCALE trial [2][3].

These medications require subcutaneous injection, typically into the abdomen, thigh, or upper arm. Mounjaro and Wegovy are administered once weekly, making them more convenient than Saxenda, which requires daily injection. All three treatments work most effectively when combined with a reduced-calorie diet and increased physical activity, as recommended by NICE guidelines for weight management [4].

Mounjaro Weight Loss Jabs: Full Dose Range Available

Mounjaro (tirzepatide) is currently the most effective weight loss medication licensed in the UK, available at Cured Pharmacy from £135.00 per four-week supply. As the first dual GIP/GLP-1 receptor agonist, tirzepatide activates two complementary metabolic pathways, producing superior clinical outcomes compared to single-receptor medications.

The SURPASS-3 head-to-head trial demonstrated tirzepatide's advantage over insulin degludec in patients with type 2 diabetes, with participants losing an average of 11.2kg on the 15mg dose versus 2.2kg weight gain in the comparator group [1]. For weight management specifically, the SURMOUNT-1 trial showed that 91% of participants on the highest dose achieved at least 5% body weight reduction, with 57% reaching 20% or greater reduction [5].

Mounjaro KwikPens contain a pre-filled, single-dose injection system. Each pen delivers one weekly dose through a hidden needle that automatically retracts after injection. The device requires no manual dose dialling, reducing the risk of administration errors. Clinical assessment by a UK prescriber is mandatory before treatment can commence, as tirzepatide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Mounjaro Dosing Schedule

Mounjaro follows a gradual dose escalation protocol to minimise gastrointestinal side effects. Treatment begins at 2.5mg weekly for four weeks, then increases to 5mg for four weeks. Your UK prescriber will continue titrating upwards every four weeks — through 7.5mg, 10mg, 12.5mg, and finally 15mg — based on your tolerance and weight loss response. At Cured Pharmacy, we stock all six dose strengths, ensuring uninterrupted treatment progression.

Wegovy and Saxenda: Proven Semaglutide and Liraglutide Options

Wegovy (semaglutide 2.4mg) is available at Cured Pharmacy with all doses in stock, offering a well-established alternative to newer tirzepatide formulations. Semaglutide has been used in diabetes management since 2018 (as Ozempic 1mg) and was licensed for weight management in 2021 following the landmark STEP trial programme [2].

The STEP-1 trial enrolled 1,961 adults with obesity or overweight plus weight-related comorbidities, randomising participants to weekly semaglutide 2.4mg or placebo for 68 weeks. Those receiving Wegovy lost an average 14.9% of their baseline body weight, compared to 2.4% in the placebo group [2]. Importantly, 86.4% of Wegovy participants achieved at least 5% weight loss — the threshold associated with meaningful improvements in cardiovascular risk factors.

Saxenda (liraglutide 3mg) provides a daily injection option for patients who prefer or require more frequent dosing. The SCALE Obesity and Prediabetes trial demonstrated average weight loss of 8.0% versus 2.6% with placebo over 56 weeks [3]. Whilst liraglutide produces more modest weight reduction than semaglutide or tirzepatide, it remains a valuable option for patients with specific clinical considerations or those who have previously responded well to daily GLP-1 therapy.

Choosing Between Wegovy and Saxenda

Wegovy suits patients seeking once-weekly administration with robust clinical evidence — the STEP trials enrolled over 4,500 participants and demonstrated consistent 15% average weight reduction [2]. Saxenda may be preferred by those who respond better to daily dosing or have contraindications to longer-acting GLP-1 agonists. Both medications require gradual dose escalation over 4-5 weeks to reach therapeutic levels whilst minimising nausea and gastrointestinal discomfort.

Why All Doses Matter: Avoiding Treatment Interruption

Weight loss injection therapy requires consistent dose escalation over 16-20 weeks to reach therapeutic levels. Interruptions due to stock shortages can compromise treatment efficacy and increase the risk of side effects when restarting. The MHRA and manufacturer guidance both emphasise that missing more than two consecutive doses may necessitate restarting the titration schedule from the beginning, delaying your weight loss goals by several months.

At Cured Pharmacy, we maintain stock across all dose strengths for Mounjaro (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg), Wegovy (0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg), and Saxenda (6mg/ml pens for daily 0.6mg through 3mg dosing). This comprehensive inventory ensures your treatment progresses on schedule, without the frustration of searching multiple pharmacies or rationing doses.

Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees supply chain management to anticipate demand and prevent stockouts. When you complete your free online consultation, our UK prescribers can confidently prescribe your appropriate dose knowing it will be dispensed and dispatched the same working day. This reliability is particularly important for patients stepping up from 10mg to 12.5mg or 15mg Mounjaro, where supply constraints have historically been most acute across UK pharmacies.

Oral Weight Loss Treatments: Orlistat and Alternatives

For patients who prefer oral medication or have contraindications to GLP-1 therapy, Cured Pharmacy stocks a full range of orlistat formulations. Orlistat works by inhibiting pancreatic lipase, reducing dietary fat absorption by approximately 30% [6]. Unlike GLP-1 injections that regulate appetite centrally, orlistat acts locally in the gastrointestinal tract.

Prescription-strength Orlistat 120mg and Xenical (the branded version) are available for patients with BMI 30 or above, or 28 with weight-related conditions. Lower-strength Alli 60mg and Orlos 60mg can be supplied without prescription for BMI 28 and above. Clinical trials demonstrate that orlistat 120mg three times daily produces average weight loss of 5-10% when combined with a reduced-calorie diet, compared to 3-6% with diet alone [6].

Orlistat's main side effects relate to its mechanism of action — unabsorbed fat passes through the digestive system, causing oily stools, flatulence, and faecal urgency if dietary fat intake is too high. These effects actually reinforce dietary adherence, as patients quickly learn to moderate fat consumption. Orlistat also reduces absorption of fat-soluble vitamins (A, D, E, K), so a daily multivitamin taken at bedtime (at least two hours after the last orlistat dose) is recommended.

When to Consider Oral Options

Orlistat suits patients with needle phobia, those with BMI 28-30 where injectable therapy may not be first-line, or individuals seeking a lower-cost option for modest weight reduction. It works best when dietary fat intake is distributed evenly across meals and kept below 30% of total calories. Patients should be aware that orlistat does not suppress appetite — weight loss depends entirely on adherence to a reduced-calorie, lower-fat eating plan.

How to Order Weight Loss Jabs from Cured Pharmacy

All weight loss medications at Cured Pharmacy require clinical assessment by a UK-registered prescriber before dispensing. The process is straightforward: select your preferred treatment, complete the free online consultation questionnaire, and a prescriber will review your submission within hours during working days. If approved, your medication is dispensed the same day and dispatched via tracked courier in discreet, unmarked packaging.

Our transparent pricing model shows exact costs before you begin the consultation — no hidden fees, no subscription traps, no inflated 'membership' charges. Mounjaro starts from £135.00 per four-week supply, with the exact price determined by your prescribed dose. Wegovy pricing begins at £135.00, and Saxenda from £135.00. These prices include the prescriber consultation, medication, and delivery to any UK address.

Cured Pharmacy is registered with the General Pharmaceutical Council (GPhC 9012511) and operates under the supervision of superintendent pharmacist Tarun Kumar (GPhC 2233073). We source all medications through licensed UK wholesalers and verify every batch against MHRA-approved product licences. When you order weight loss jabs from Cured Pharmacy, you receive genuine UK-licensed medication with full patient information leaflets, dispensed by qualified professionals who are accountable to UK regulatory standards. For questions about your treatment, our pharmacy team is available on (+44) 116 4646009 during business hours.

What to Expect During Your Consultation

The online assessment takes under three minutes and covers your medical history, current medications, weight loss goals, and any contraindications to GLP-1 therapy. Questions include previous weight loss attempts, cardiovascular history, thyroid conditions, pancreatitis history, and current BMI. Our prescribers review every consultation individually — this is not an automated approval system. If your assessment raises clinical concerns, a prescriber will contact you directly to discuss alternative options or request additional information from your GP.

Scientific References

1. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
5. Garvey, W. T., et al. (2023). Tirzepatide once weekly for the treatment of obesity in people without diabetes (SURMOUNT-1): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet, 402(10402), 580–591. https://doi.org/10.1016/S0140-6736(23)01200-X [accessed 13 August 2026]
6. Torgerson, J. S., et al. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
7. Wilding, J. P. H., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725 [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to diet, exercise, and treatment protocols. GLP-1 receptor agonists are not suitable for everyone and may cause side effects. Your prescriber will discuss risks and benefits during consultation.